SMS Pharmaceuticals Ltd
Pharmaceuticals & Biotechnology | Small Cap
SMS Pharmaceuticals demonstrates a mixed financial profile. The company shows strong solvency and profitability, indicating a solid foundation and efficient management of resources. Revenue and asset growth are also robust, suggesting expansion and effective use of assets. However, the company faces challenges in efficiency, particularly in inventory and receivables management. Earnings per share and net income growth have been volatile, reflecting potential instability in earnings. Liquidity is adequate, but there is room to improve short-term financial obligations. Overall, SMS Pharmaceuticals exhibits financial strengths but needs to address certain operational inefficiencies and earnings inconsistencies to enhance its long-term financial health.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio6.00
- Financial Ratio4.40
- Profitability Ratio10.00
- Efficiency Ratio2.33
- Coverage Ratio8.80
- Solvency Ratio10.00
- Liquidity Ratio5.18
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursStrong Bullish
- 4 HoursBullish
- 1 DayBearish
- 1 WeekNeutral
- 1 MonthNeutral
SMS Pharmaceuticals demonstrates a mixed financial profile. The company shows strong solvency and profitability, indicating a solid foundation and efficient management of resources. Revenue and asset growth are also robust, suggesting expansion and effective use of assets. However, the company faces challenges in efficiency, particularly in inventory and receivables management. Earnings per share and net income growth have been volatile, reflecting potential instability in earnings. Liquidity is adequate, but there is room to improve short-term financial obligations. Overall, SMS Pharmaceuticals exhibits financial strengths but needs to address certain operational inefficiencies and earnings inconsistencies to enhance its long-term financial health.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
40.02
Industry Median
28.93
Small Cap Median
26.92
P/E RATIO
34.36
P/B RATIO
4.46
Industry Median
3.18
Small Cap Median
2.63
P/S RATIO
3.90
Industry Median
3.41
Small Cap Median
2.40
Others
PEG RATIO
0.00
EV/EBITDA RATIO
19.93
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹374.15 as on Jun 18, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Quarterly Report⬤7th Feb 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
Concall Report⬤11th Nov 25
Q2 & H1 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
The growth ratios show positive trends in revenue and asset growth, but inconsistencies in earnings per share and net income growth may indicate earnings instability. While revenue and asset growth demonstrate the company's ability to expand, the negative growth in earnings per share and net income requires attention to ensure sustainable profitability. Improving earnings stability is crucial for long-term growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -7.64 | 0.38 | 35.82 | 10.44 | 13.28 |
| Operating Profit Growth Rate | -4.96 | -52.17 | 112.73 | 18.8 | 23.02 |
| Earnings Per Share (EPS) Growth | -0.41 | -111.29 | -808.43 | 32.65 | 39.62 |
| Asset Growth Rate | 5.91 | 2.33 | 17.5 | 11.51 | 18.13 |
| Net Income Growth Rate | -1.59 | -111.29 | -814.29 | 38 | 47.83 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial ratios show mixed results, with adequate earnings per share and book value per share, but low dividend per share and high capital expenditures. While earnings per share and book value per share demonstrate the company's profitability and asset value, the low dividend per share and high capital expenditures suggest a focus on reinvesting earnings rather than distributing them to shareholders. Balancing these factors is crucial for maintaining shareholder satisfaction and funding future growth.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 7.75 | -0.88 | 6.25 | 7.67 | 11.33 |
| Cash Earnings Per Share (Cash EPS) | 11.75 | 3.12 | 10.25 | 11.44 | 15.78 |
| Book Value Per Share | 58.75 | 57.5 | 67 | 71.11 | 87.22 |
| Dividend Per Share (DPS) | 0.29 | 0.3 | 0.41 | 0.39 | 0.44 |
| Capital Expenditures (CapEx) | 27 | 30 | 52 | 123 | 131 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The profitability ratios demonstrate the company's ability to generate profits from its revenue and assets. The company is efficient in managing its operations and generating profit from its core business activities.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 15.96 | 4.41 | 11.99 | 13.41 | 14.77 |
| Return on Capital Employed (ROCE) | 13 | 4 | 12 | 13 | 13 |
| Return on Equity (ROE) | 13.19 | -1.52 | 9.33 | 10.78 | 12.99 |
| Return on Assets (ROA) | 13.37 | 6.25 | 11.32 | 12.06 | 12.56 |
| Operating Margin | 22.12 | 10.54 | 16.5 | 17.75 | 19.28 |
| Net Margin | 11.92 | -1.34 | 7.05 | 8.81 | 11.5 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The efficiency ratios suggest that the company faces challenges in effectively managing its assets and operations. There is room for improvement in optimizing asset utilization, inventory turnover, and receivables collection to enhance overall efficiency and profitability. Focus should be on improving asset turnover and streamlining operations to improve the company's performance.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.19 | 1.27 | 1.62 | 1.47 | 1.66 |
| Inventory Turnover Ratio | 2.25 | 2.1 | 2.73 | 2.61 | 2.38 |
| Receivables Turnover Ratio | 6.71 | 5.3 | 3.69 | 3.57 | 4.23 |
| Days Sales in Inventory Ratio | 162.22 | 173.81 | 133.7 | 139.85 | 153.36 |
| Receivable Days | 54.4 | 68.87 | 98.92 | 102.24 | 86.29 |
| Capital Turnover Ratio | 0.83 | 0.9 | 1.08 | 1.01 | 0.93 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The coverage ratios suggest that the company has a strong ability to meet its interest and dividend obligations. The company's ability to cover its interest and dividend payments indicates financial stability and a lower risk of financial distress.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 4.58 | 1.23 | 3.75 | 5.84 | 6.09 |
| Equity Dividend Coverage Ratio | 25 | 14.29 | 20 | 25 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The solvency position shows a healthy capital structure with a conservative approach to debt. The company is relying more on equity than debt to finance its operations. The company's equity is significantly higher than its debt, demonstrating financial stability and a lower risk of financial distress.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.25 | 0.21 | 0.19 | 0.18 | 0.18 |
| Debt to Equity Ratio | 0.33 | 0.27 | 0.23 | 0.22 | 0.22 |
| Equity Ratio | 0.75 | 0.79 | 0.81 | 0.82 | 0.82 |
| Debt To Asset Ratio | 0.18 | 0.14 | 0.12 | 0.12 | 0.13 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The liquidity position, while not exceptional, suggests the company has some capacity to meet its short-term obligations. The current and quick ratios indicate an ability to cover current liabilities with current assets, but the cash ratio and operating cash flow ratio suggest reliance on less liquid assets. The weighted average calculation provides a balanced view, but there is room to improve the company's immediate liquidity position to handle unforeseen expenses or investment opportunities.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.64 | 1.43 | 1.48 | 1.54 | 1.68 |
| Quick Ratio | 0.58 | 0.68 | 0.86 | 0.77 | 0.81 |
| Cash Ratio | 0.2 | 0.02 | 0.1 | 0.11 | 0.11 |
| Operating Cash Flow Ratio | 0.19 | 0.07 | 0.13 | 0.22 | 0.15 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 32.75 | Overvalued | 58.00 | 6.42 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 77.43 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 25.66 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Innova Captab Ltd | 7.36 | 37.88 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Hikal Ltd | 7.13 | -50.15 | Neutral | 220.00 | -3.95 | -49.00 |
| 6 | RPG Life Sciences Ltd | 7.12 | 32.71 | Neutral | 147.00 | 69.64 | 115.00 |
| 7 | Morepen Laboratories Ltd | 7.12 | 29.50 | Neutral | 126.00 | 1.21 | 96.00 |
| 8 | Alembic Ltd | 7.06 | 7.59 | Undervalued | 90.00 | 4.85 | 317.00 |
| 9 | Syncom Formulations (India) Ltd | 6.92 | 17.26 | Undervalued | 77.00 | 0.81 | 76.00 |
| 10 | Hester Biosciences Ltd | 6.54 | 31.47 | Neutral | 87.00 | 61.24 | 57.00 |
| 11 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 12 | SMS Pharmaceuticals Ltd | 5.94 | 34.36 | Neutral | 171.00 | 9.35 | 102.00 |
| 13 | Gufic BioSciences Ltd | 5.49 | 55.88 | Neutral | 151.00 | 6.30 | 64.00 |
| 14 | Dishman Carbogen Amcis Ltd | 5.38 | 27.35 | Neutral | 566.00 | -2.45 | 97.00 |
| 15 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.36 | Undervalued | 269.00 | 4.69 | 138.00 |
| 16 | Indoco Remedies Ltd | 5.26 | -22.51 | Neutral | 142.00 | -0.61 | -99.00 |
| 17 | Aarti Drugs Ltd | 5.07 | 17.33 | Undervalued | 309.00 | 18.54 | 195.00 |
| 18 | Orchid Pharma Ltd | 4.85 | 248.95 | Neutral | 41.00 | 8.91 | 21.00 |
| 19 | Sun Pharma Advanced Research Company Ltd | 4.35 | 5.07 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 20 | Solara Active Pharma Sciences Ltd | 4.34 | -276.85 | Neutral | 187.00 | -1.50 | -7.00 |
| 21 | Zota Health Care Ltd | 3.97 | -59.69 | Neutral | 19.00 | 8.06 | -74.00 |
The management of SMS Pharmaceuticals exhibits a mixed performance. While the company has demonstrated sales growth, there are inconsistencies in quarterly sales and profit growth. The operating profit margin has seen fluctuations, and a high cash conversion cycle raises concerns about operational efficiency. While promoter holding is good, these factors suggest a need for careful monitoring.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 66.27% | Good promoter holding indicates aligned interests. |
| Sales Growth (2024) | 35.86% | Strong sales growth in 2024. | |
| CONS | Cash Conversion Cycle (2025) | 237 days | High cash conversion cycle indicates inefficiency. |
| OPM Fluctuation | Unstable operating profit margins. |
Financial Performance & Growth
SMS Pharmaceuticals has demonstrated fluctuating financial performance. The inconsistency in quarterly sales and profit growth raises concerns. While sales have grown, recent trends require attention.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Sales Growth % | -28.34-5.60% | -11.39-36.71% | 0.42% | 35.86% | 10.36% |
| Net Profit - | 28-40 | 32-63 | -7 | 50 | 69 |
Capital Efficiency & Returns
The capital efficiency of SMS Pharmaceuticals is mixed. The ROCE has fluctuated over the years, indicating variability in capital productivity. The cash conversion cycle is high, suggesting inefficiencies in working capital management.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| ROCE % | 17-18% | 13-17% | 4% | 12% | 13% |
| Cash Conversion Cycle | 105-131 | 146-270 | 230 | 192 | 237 |
Financial Health & Prudence
SMS Pharmaceuticals exhibits moderate financial health. The dividend payout is inconsistent.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Dividend Payout % | 5-7% | 4% | -36% | 7% | 5% |
Strategic & Operational Indicators
The operational efficiency of SMS Pharmaceuticals shows some challenges. The debtor days and inventory days are high, leading to a longer cash conversion cycle. This indicates a need for better working capital management to improve efficiency.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Debtor Days | 18-20 | 34-68 | 104 | 122 | 95 |
| Inventory Days | 114-170 | 148-333 | 243 | 201 | 238 |
| Days Payable | 49-82 | 70-97 | 117 | 130 | 95 |
SMS Pharmaceuticals faces moderate risks including segment performance volatility. The company's financial leverage and high cash conversion cycle add to the risk profile. Continuous monitoring and strategic adjustments are necessary to mitigate these risks.
Off-balance sheet exposure quantification
Off-balance sheet exposure includes lease liabilities which has been reduced to zero in Mar 2025. There is no significant off-balance sheet exposure.
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Lease Liabilities | 5 | 4 | 3 | 2 | 1 | 0 |
Segment performance volatility
Segment performance volatility is evident from the quarterly results. The YOY Sales Growth % and YOY Profit Growth % fluctuate significantly, indicating instability in performance.
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| YOY Sales Growth % | 144.41% | 110.19% | 4.52% | 8.52% | 64.49% | 0.98% |
| YOY Profit Growth % | 0.81% | 173.14% | 683.58% | 205.32% | 177.81% | 17.59% |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10378.36Bullish
- SMA 20376.92Bullish
- SMA 50379.10Bullish
- EMA 10378.88Bullish
- EMA 20378.13Bullish
- EMA 50377.78Bullish
- DEMA 10380.18Bearish
- DEMA 20378.61Bullish
- DEMA 50378.34Bullish
- TEMA 10380.82Bearish
- TEMA 20379.61Bullish
- TEMA 50379.12Bullish
- MACD0.58Bullish
- ADX25.15Strong Trend
- IndicatorValueSignal
- RSI54.61Neutral
- CCI62.66Neutral
- ROC 92.41Bullish
- ROC 141.33Bullish
- ROC 250.90Bullish
- Stoch K60.60Neutral
- Stoch D59.99Neutral
- IndicatorValueSignal
- BB Upper383.23Neutral
- BB Middle376.92Neutral
- BB Lower370.60Neutral
- ATR3.57Low Volatility
- IndicatorValueSignal
- MFI55.05Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10376.98Bullish
- SMA 20377.61Bullish
- SMA 50375.24Bullish
- EMA 10378.05Bullish
- EMA 20377.76Bullish
- EMA 50377.85Bullish
- DEMA 10378.80Bullish
- DEMA 20378.17Bullish
- DEMA 50375.25Bullish
- TEMA 10379.92Bullish
- TEMA 20377.85Bullish
- TEMA 50378.94Bullish
- MACD0.33Bullish
- ADX36.03Strong Trend
- IndicatorValueSignal
- RSI55.05Neutral
- CCI34.84Neutral
- ROC 91.09Bullish
- ROC 140.98Bullish
- ROC 250.18Bullish
- Stoch K60.49Neutral
- Stoch D58.76Neutral
- IndicatorValueSignal
- BB Upper383.80Neutral
- BB Middle377.61Neutral
- BB Lower371.41Neutral
- ATR5.02Low Volatility
- IndicatorValueSignal
- MFI62.16Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10377.09Bullish
- SMA 20378.27Bullish
- SMA 50381.36Bearish
- EMA 10377.36Bullish
- EMA 20377.07Bullish
- EMA 50381.59Bearish
- DEMA 10377.79Bullish
- DEMA 20376.44Bullish
- DEMA 50372.99Bullish
- TEMA 10377.53Bullish
- TEMA 20379.35Bullish
- TEMA 50N/AN/A
- MACD-0.29Bullish
- ADX31.63Strong Trend
- IndicatorValueSignal
- RSI52.86Neutral
- CCI6.94Neutral
- ROC 9-0.68Bearish
- ROC 14-0.78Bearish
- ROC 256.95Bullish
- Stoch K31.59Neutral
- Stoch D21.17Neutral
- IndicatorValueSignal
- BB Upper387.00Neutral
- BB Middle378.27Neutral
- BB Lower369.54Neutral
- ATR8.72Low Volatility
- IndicatorValueSignal
- MFI43.78Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10376.41Bearish
- SMA 20374.85Bearish
- SMA 50396.18Bearish
- SMA 100376.87Bearish
- SMA 200334.41Bullish
- EMA 10375.99Bearish
- EMA 20379.11Bearish
- EMA 50384.22Bearish
- EMA 100372.67Bullish
- EMA 200342.98Bullish
- DEMA 10375.11Bearish
- DEMA 20371.54Bullish
- DEMA 50387.38Bearish
- DEMA 100403.41Bearish
- DEMA 200394.78Bearish
- TEMA 10377.83Bearish
- TEMA 20371.06Bullish
- TEMA 50373.13Bullish
- TEMA 100398.63Bearish
- TEMA 200410.24Bearish
- MACD-5.02Bullish
- ADX15.40Weak Trend
- IndicatorValueSignal
- RSI45.32Neutral
- CCI-9.87Neutral
- ROC 141.33Bullish
- ROC 25-7.40Bearish
- Stoch K50.10Neutral
- Stoch D53.56Neutral
- IndicatorValueSignal
- BB Upper403.43Neutral
- BB Middle374.85Neutral
- BB Lower346.26Neutral
- ATR15.84Low Volatility
- IndicatorValueSignal
- MFI56.12Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20380.16Bullish
- SMA 50319.18Bullish
- EMA 20374.32Bullish
- EMA 50333.66Bullish
- DEMA 20402.31Bearish
- DEMA 50388.15Bearish
- TEMA 20397.29Bearish
- TEMA 50404.99Bearish
- MACD18.78Bearish
- ADX43.29Strong Trend
- IndicatorValueSignal
- RSI57.49Neutral
- CCI81.68Neutral
- ROC 142.05Bullish
- ROC 2523.18Bullish
- Stoch K22.16Neutral
- Stoch D29.46Neutral
- IndicatorValueSignal
- BB Upper437.63Neutral
- BB Middle380.15Neutral
- BB Lower322.68Neutral
- ATR37.19Low Volatility
- IndicatorValueSignal
- MFI48.73Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 6360.00Bullish
- SMA 12311.03Bullish
- SMA 24285.44Bullish
- EMA 6358.87Bullish
- EMA 12326.28Bullish
- EMA 24282.47Bullish
- DEMA 6390.40Bearish
- DEMA 12376.33Bearish
- DEMA 24351.98Bullish
- TEMA 6391.84Bearish
- TEMA 12390.37Bearish
- TEMA 24373.31Bearish
- MACD68.23Bullish
- ADX36.60Strong Trend
- IndicatorValueSignal
- RSI64.28Neutral
- CCI146.21Overbought
- ROC 2580.74Bullish
- ROC 50294.92Bullish
- Stoch K60.93Neutral
- Stoch D57.06Neutral
- IndicatorValueSignal
- BB Upper404.93Neutral
- BB Middle281.68Neutral
- BB Lower158.43Neutral
- ATR59.87High Volatility
- IndicatorValueSignal
- MFI88.14Overbought